Cambridge Investment Research Advisors
AXDX

Cambridge Investment Research Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,452
Closed -$20K – 3147
2023
Q2 		$20K Hold
2,452
– – ﹤0.01% 3123
2023
Q1 		$17K Buy
2,452
+1,000
+69% +$6.01K ﹤0.01% 3112
2022
Q4 		$10K Hold
1,452
– – ﹤0.01% 3077
2022
Q3 		$22K Buy
+1,452
New +$24K ﹤0.01% 2998

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $139M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors's AXDX Position: Q3 2023 in Review

Cambridge Investment Research Advisors sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 2,452 shares — an estimated $20K sold.

Cambridge Investment Research Advisors first reported a position in AXDX in Q3 2022 and held it in 4 quarters. The position peaked at $22K in Q3 2022. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

  • Cambridge Investment Research Advisors reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,452 Accelerate Diagnostics shares in Q3 2023, an estimated $20K.
  • Cambridge Investment Research Advisors first reported a position in Accelerate Diagnostics in Q3 2022 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Accelerate Diagnostics position peaked at $22K in Q3 2022.
  • 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.